China Biologic Products to Participate in the Rodman & Renshaw Annual Global Investment Conference
September 03 2009 - 8:00AM
PR Newswire (US)
TAI'AN, China, Sept. 3 /PRNewswire-Asia-FirstCall/ -- China
Biologic Products, Inc. (OTC:CBPO) (BULLETIN BOARD: CBPO) ("China
Biologic," or the "Company"), one of the leading plasma-based
pharmaceutical companies in the People's Republic of China ("PRC"),
operating through its indirect majority-owned subsidiaries,
Shandong Taibang Biological Products Co. Ltd. ("Taibang") and
Chongqing Dalin Biologic Technologies Co., Ltd. ("Dalin") and its
equity investment in Xi'an Huitian Blood Products Co., Ltd.
("Huitian"), today announced that the Company's management team
will attend the upcoming Rodman & Renshaw Annual Global
Investment Conference. The date, time and location of China
Biologic's presentation at the conference are as follows: Date:
Thursday, September 10, 2009 Time: 12.05 p.m. Eastern Time Venue:
Asia Track New York Palace Hotel New York, NY During the
conference, the Company will be available to meet with analysts and
portfolio managers. Interested parties and investors who wish to
meet with China Biologic's management may contact or call (212)
430-1782. Participation in the Rodman & Renshaw Annual Global
Investment Conference is by invitation only. About Rodman &
Renshaw, LLC. Rodman & Renshaw, LLC is a full service
investment bank dedicated to providing investment banking services
to companies that have significant capital needs, along with
research and sales and trading services to investor clients. Rodman
is a leader in the PIPE (private investment in public equity) and
RD (registered direct placements) transaction markets according to
PrivateRaise a service of DealFlow Media Inc. and Sagient Research
Systems, Inc. About China Biologic Products, Inc. China Biologic
Products, Inc. (the "Company"), through its indirect majority-owned
subsidiaries, Shandong Taibang Biological Products Co. Ltd. and
Chongqing Dalin Biologic Technologies Co., Ltd, and its equity
investment in Xi'an Huitian Blood Products Co., Ltd., is currently
the largest non-state-owned plasma-based biopharmaceutical company
in China. The Company is a fully integrated biologic products
company with plasma collection, production and manufacturing,
research and development, and commercial operations. The Company's
plasma-based biopharmaceutical products are irreplaceable during
medical emergencies, and are used for the prevention and treatment
of various diseases. It sells its products to hospitals and other
healthcare facilities in China. For more information, please
contact: Company Contact: Mr. Y. Tristan Kuo Chief Financial
Officer China Biologic Products, Inc. Tel: +86-538-6202206 Email:
Web: http://www.chinabiologic.com/ Investor Relations Contact: Mr.
Crocker Coulson, President CCG Investor Relations Tel:
+1-646-213-1915 (NY office) or Mr. Gary Chin Tel: +1-646-213-1909
Email: Web: http://www.ccgirasia.com/ DATASOURCE: China Biologic
Products, Inc. CONTACT: Company Contact: Mr. Y. Tristan Kuo, Chief
Financial Officer of China Biologic Products, Inc.,
+86-538-6202206, or ; Investor Relations Contact: Mr. Crocker
Coulson, President of CCG Investor Relations, +1-646-213-1915 (NY
office) or Mr. Gary Chin, +1-646-213-1909, or Web Site:
http://www.chinabiologic.com/
Copyright